Immuno-Oncology

Celgene is exploring immuno-oncology therapies targeting multiple cell types associated with anti-tumor responses. In collaboration with key partners, Celgene is investigating B-cell functions relevant to tumor immunology,1,2 stimulating T-cell immunity against hematologic and solid tumors,3-7 modulating innate immunity5-9 and NK cell function to enhance tumor cell killing,10-12 reducing immunosuppressive effects of suppressor cells,11,12 and modulating the metabolic state of immune cells and the tumor microenvironment to stimulate antitumor response in cancer patients.13,14 Although tumor cells use multiple mechanisms to evade immune response3,4,15 development of these immunotherapeutic approaches may assist in the elimination of tumor cells by the immune system.

Targeting Multiple Immune Cell Types in Immuno-Oncology

References

  1. Namm JP, et al. J Surg Oncol. 2012;105:431-435.
  2. Lapalombella R, et al. Blood. 2010;115:2619-2629.
  3. Disis M. Semin Oncol. 2014;41:S3-S13.
  4. Harris TJ, Drake CG. J Immunother Cancer. 2013;1:12.
  5. Pardoll DM. Nat Rev Cancer. 2012;12:253-264.
  6. Gandhi AK, et al. Br J Haematol. 2014;164:811-821.
  7. Corral LG, et al. J Immunol. 1999;163:380-386.
  8. Weiskopf K, et al. Science. 2013;341:88-91.
  9. Herter S, et al. J Immunol. 2014;192:2252-2260.
  10. Wu L, et al. Clin Cancer Res. 2008;14:4650-4657.
  11. Zhang L, et al. Am J Hematol. 2009;84:553-559.
  12. Kang L, et al. Front Immunol. 2013;4:1-13.
  13. Young A, et al. Cancer Discovery. 2014;4:879-888.
  14. Pearce EL, et al. Science. 2013;342:1242454.
  15. Corthay A. Front Immunol. 2014;5:1-8.